Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Influenza
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Masking Description: This is a parallel-group dose-ranging study with 8 arms that is participant, investigator and observer-blindedPrimary Purpose: Prevention
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04782323
- Collaborators
- Not Provided
- Investigators
- Study Chair: Therapeutic Area Head Seqirus